SCHEMBL369485

SCHEMBL369485

c1ccc2[nH]c(-c3nc4ncncc4[nH]3)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.61
METAP1 P53582 3/20 0.61
NPC1 O15118 11/20 0.61
RAB9A P51151 11/20 0.61
KDM4E B2RXH2 9/20 0.61
ALDH1A1 P00352 8/20 0.61
PKM P14618 5/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
TP53 P04637 4/20 0.61
HSD17B10 Q99714 4/20 0.61
ABCB11 O95342 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
ADORA3 P0DMS8 3/20 0.51
ADORA2A P29274 1/20 0.51
ADORA1 P30542 1/20 0.51
PKN1 Q16512 1/20 0.50
PKN2 Q16513 1/20 0.50
LDHA P00338 1/20 0.50
EPHX2 P34913 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680854 0.80 METAP2 (0.65) METAP2METAP1NPC1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL4456676 0.79 METAP2 (0.63) METAP2METAP1NPC1RAB9AALDH1A1
SCHEMBL30561047 0.78 NPC1 (1.00) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL30634854 0.78 NPC1 (1.00) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL172216 0.78 NPC1 (1.00) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL12833538 0.78 KDM4E (0.68) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL2396563 0.77 METAP2 (0.57) METAP2METAP1NPC1RAB9AKDM4E
Water SCHEMBL9817804 0.76 NPC1 (0.95) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL4924097 0.76 METAP2 (1.00) METAP2METAP1NPC1RAB9AKDM4E
SCHEMBL30174323 0.76 NPC1 (0.64) METAP2METAP1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593455-B1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2015-03-18 EP disclosed
EP-2593455-A1 PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-05-22 EP disclosed
US-8293736-B2 Purine compounds selective for PI3K P110 delta, and methods of use F. HOFFMANN LA ROCHE AG (CH) 2012-10-23 US disclosed
WO-2012007493-A1 PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 WO disclosed
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015931-A1 PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE PIK3CA, PIK3CD, PIK3CG METAP2 3060/4885METAP1 3242/4885NPC1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.